1
|
Tratwal J, Falgayrac G, During A, Bertheaume N, Bataclan C, Tavakol DN, Campos V, Duponchel L, Daley GQ, Penel G, Chauveau C, Naveiras O. Raman microspectroscopy reveals unsaturation heterogeneity at the lipid droplet level and validates an in vitro model of bone marrow adipocyte subtypes. Front Endocrinol (Lausanne) 2022; 13:1001210. [PMID: 36506047 PMCID: PMC9727239 DOI: 10.3389/fendo.2022.1001210] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Accepted: 10/04/2022] [Indexed: 11/24/2022] Open
Abstract
Bone marrow adipocytes (BMAds) constitute the most abundant stromal component of adult human bone marrow. Two subtypes of BMAds have been described, the more labile regulated adipocytes (rBMAds) and the more stable constitutive adipocytes (cBMAds), which develop earlier in life and are more resilient to environmental and metabolic disruptions. In vivo, rBMAds are enriched in saturated fatty acids, contain smaller lipid droplets (LDs) and more readily provide hematopoietic support than their cBMAd counterparts. Mouse models have been used for BMAds research, but isolation of primary BMAds presents many challenges, and thus in vitro models remain the current standard to study nuances of adipocyte differentiation. No in vitro model has yet been described for the study of rBMAds/cBMAds. Here, we present an in vitro model of BM adipogenesis with differential rBMAd and cBMAd-like characteristics. We used OP9 BM stromal cells derived from a (C57BL/6xC3H)F2-op/op mouse, which have been extensively characterized as feeder layer for hematopoiesis research. We observed similar canonical adipogenesis transcriptional signatures for spontaneously-differentiated (sOP9) and induced (iOP9) cultures, while fatty acid composition and desaturase expression of Scd1 and Fads2 differed at the population level. To resolve differences at the single adipocyte level we tested Raman microspectroscopy and show it constitutes a high-resolution method for studying adipogenesis in vitro in a label-free manner, with resolution to individual LDs. We found sOP9 adipocytes have lower unsaturation ratios, smaller LDs and higher hematopoietic support than iOP9 adipocytes, thus functionally resembling rBMAds, while iOP9 more closely resembled cBMAds. Validation in human primary samples confirmed a higher unsaturation ratio for lipids extracted from stable cBMAd-rich sites (femoral head upon hip-replacement surgery) versus labile rBMAds (iliac crest after chemotherapy). As a result, the 16:1/16:0 fatty acid unsaturation ratio, which was already shown to discriminate BMAd subtypes in rabbit and rat marrow, was validated to discriminate cBMAds from rBMAd in both the OP9 model in vitro system and in human samples. We expect our model will be useful for cBMAd and rBMAd studies, particularly where isolation of primary BMAds is a limiting step.
Collapse
Affiliation(s)
- Josefine Tratwal
- Laboratory of Regenerative Hematopoiesis, Ecole Polytechnique Fédérale de Lausanne (EPFL) & Department of Biomedical Sciences, University of Lausanne (UNIL), Lausanne, Switzerland
| | - Guillaume Falgayrac
- Univ. Lille, CHU Lille, Univ. Littoral Côte d’Opale, ULR 4490 - MABLab- Marrow Adiposity Laboratory, Lille, France
| | - Alexandrine During
- Univ. Lille, CHU Lille, Univ. Littoral Côte d’Opale, ULR 4490 - MABLab- Marrow Adiposity Laboratory, Lille, France
| | - Nicolas Bertheaume
- Univ. Lille, CHU Lille, Univ. Littoral Côte d’Opale, ULR 4490 - MABLab- Marrow Adiposity Laboratory, Lille, France
| | - Charles Bataclan
- Laboratory of Regenerative Hematopoiesis, Ecole Polytechnique Fédérale de Lausanne (EPFL) & Department of Biomedical Sciences, University of Lausanne (UNIL), Lausanne, Switzerland
| | - Daniel N. Tavakol
- Laboratory of Regenerative Hematopoiesis, Ecole Polytechnique Fédérale de Lausanne (EPFL) & Department of Biomedical Sciences, University of Lausanne (UNIL), Lausanne, Switzerland
| | - Vasco Campos
- Laboratory of Regenerative Hematopoiesis, Ecole Polytechnique Fédérale de Lausanne (EPFL) & Department of Biomedical Sciences, University of Lausanne (UNIL), Lausanne, Switzerland
| | - Ludovic Duponchel
- Univ. Lille, CNRS, UMR 8516 - LASIRe - Laboratoire Avancé de Spectroscopie pour les Intéractions la Réactivité et l’Environnement, Lille, France
| | - George Q. Daley
- Division of Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, Boston, MA, United States
| | - Guillaume Penel
- Univ. Lille, CHU Lille, Univ. Littoral Côte d’Opale, ULR 4490 - MABLab- Marrow Adiposity Laboratory, Lille, France
| | - Christophe Chauveau
- Univ. Lille, CHU Lille, Univ. Littoral Côte d’Opale, ULR 4490 - MABLab- Marrow Adiposity Laboratory, Lille, France
| | - Olaia Naveiras
- Laboratory of Regenerative Hematopoiesis, Ecole Polytechnique Fédérale de Lausanne (EPFL) & Department of Biomedical Sciences, University of Lausanne (UNIL), Lausanne, Switzerland
- Service of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Service of Hematology, Department of Laboratory Medicine Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- *Correspondence: Olaia Naveiras,
| |
Collapse
|
2
|
Cronk SM, Kelly-Goss MR, Ray HC, Mendel TA, Hoehn KL, Bruce AC, Dey BK, Guendel AM, Tavakol DN, Herman IM, Peirce SM, Yates PA. Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy. Stem Cells Transl Med 2015; 4:459-67. [PMID: 25769654 DOI: 10.5966/sctm.2014-0108] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Accepted: 02/09/2015] [Indexed: 12/15/2022] Open
Abstract
Diabetic retinopathy is characterized by progressive vascular dropout with subsequent vision loss. We have recently shown that an intravitreal injection of adipose-derived stem cells (ASCs) can stabilize the retinal microvasculature, enabling repair and regeneration of damaged capillary beds in vivo. Because an understanding of ASC status from healthy versus diseased donors will be important as autologous cellular therapies are developed for unmet clinical needs, we took advantage of the hyperglycemic Akimba mouse as a preclinical in vivo model of diabetic retinopathy in an effort aimed at evaluating therapeutic efficacy of adipose-derived stem cells (mASCs) derived either from healthy, nondiabetic or from diabetic mice. To these ends, Akimba mice received intravitreal injections of media conditioned by mASCs or mASCs themselves, subsequent to development of substantial retinal capillary dropout. mASCs from healthy mice were more effective than diabetic mASCs in protecting the diabetic retina from further vascular dropout. Engrafted ASCs were found to preferentially associate with the retinal vasculature. Conditioned medium was unable to recapitulate the vasoprotection seen with injected ASCs. In vitro diabetic ASCs showed decreased proliferation and increased apoptosis compared with healthy mASCs. Diabetic ASCs also secreted less vasoprotective factors than healthy mASCs, as determined by high-throughput enzyme-linked immunosorbent assay. Our findings suggest that diabetic ASCs are functionally impaired compared with healthy ASCs and support the utility of an allogeneic injection of ASCs versus autologous or conditioned media approaches in the treatment of diabetic retinopathy.
Collapse
Affiliation(s)
- Stephen M Cronk
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Molly R Kelly-Goss
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - H Clifton Ray
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Thomas A Mendel
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Kyle L Hoehn
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Anthony C Bruce
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Bijan K Dey
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Alexander M Guendel
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Daniel N Tavakol
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Ira M Herman
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Shayn M Peirce
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| | - Paul A Yates
- Departments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA
| |
Collapse
|